醫藥品業界與政府：對於政府政策與生物製藥業界的影響

醫藥品業界與政府：對於政府政策與生物製藥業界的影響 是由出版商Decision Resources, Inc.在2008年09月所出版的。 這份英文市場調查報告書包含44 Pages 價格從美金2250起跳。

簡介

目錄

Abstract

Introduction

This is a critical time in U.S. history for examination of the delivery of healthcare services. Some 47 million people in the United States lack healthcare coverage; the country spends $2.2 trillion annually on healthcare; the United States ranks 37th in terms of healthcare outcomes. Healthcare is thus in the spotlight among the population, the legislators who represent the population, and candidates in this year' s presidential elections. Certain healthcare issues - because they represent a confl uence of the pending elections, recent legislative activity, and volatile trends affecting the U.S. healthcare marketplace - have near-term and/or powerful consequences for biopharma and thus pose an opportunity for biopharma players to act now so as to best navigate change. In the current landscape, there are opportunities to tap, threats to weather, and waves to ride.

Get the Answers You Need to Shape Your Strategy

• The November elections are fast approaching. McCain? Obama? What is the outlook for biopharma if either is elected?
• Spectrum has followed developments in personalized medicine with ever-growing interest. How does recent legislation fuel the move toward personalized medicine? What are the presidential candidates' positions on this issue?
• Cost issues that threaten the traditional biopharma business model are on the table and are being served up with particular enthusiasm given the general economic situation. Is it likely that legislation approving importation and biosimilars will be enacted? What will the impact be?
• As cost-consciousness moves to the fore, the question of funding innovation ascends with it. What do stakeholders say? What does legislation affecting privacy of genetic and other patient data mean for innovation? What is the outlook for stem cell research? For clinical trials?
• Patient safety, scrutiny of messages to consumers, and personal security in the health IT arena are priority issues for the government. What steps are being taken by the government to protect the public in these areas? Which legislative activities will address these issues, and how?

Scope

• Presidential elections: positions of the candidates relevant to biopharma and select legislation; timeframe for change.
• Issues to watch: health information technology, clinical trials, affordable medications, genetic information, biosimilars, and generics.
• Recently approved legislation: GINA, FDAAA, and Medicare.
• Pending legislation: The Pharmaceutical Market Access Act. The Wired for Health Quality Act. The Healthcare Enterprise Integration Act. The PRO(TECH)T Act. The ACCESS Act. The Stem Cell Research Enhancement Act of 2007. The HOPE Act of 2007. Biologics Price Competition and Innovation Act of 2007.
• Expert Commentary: The impact of REMS on the value of a product in the pharmaceutical industry is discussed in a commentary by Covance' s Jeffrey Stoddard, M.D., VP, Medical and Scientific Affairs, Risk Management and Postmarketing Programs, and Edgar H. Adams, Sc.D., Executive Director, Epidemiology.

Mentioned in This Spectrum Report

Concepts

• Access
• Affordable medicines
• Biogenerics
• Biosimilars
• Clinical trials
• Direct-to-consumer adverting
• Drug counterfeiting
• Drug importation
• Drug reimportation
• Drug safety
• DTC advertising
• Electronic health records (EHRs)
• Elections
• Electronic medical records (EMRs)
• e-pedigrees
• FDA
• Funding
• Generic drugs
• Gene testing
• Genomics
• Genetic Information Nondiscrimination Act (GINA)
• Healthcare delivery
• Healthcare reform
• Health information technology (Health IT/HIT)
• Importation
• Legislation
• McCain
• Medicare
• Medicines
• Obama
• Personalized medicine
• Pharmacovigilance
• Presidential elections
• Privacy
• Safety
• Telemedicine
• Universal care

Table of Contents

Executive Summary

• Strategic Considerations
• Stakeholder Implications

Introduction

Select Enacted Legislation by the 110th Congress

• Genetic Information Nondiscrimination Act
• Food and Drug Administration' s Amendment Act of 2007
• Post-Approval Safety Studies
• Risk Evaluation and Mitigation Strategies
• Public Disclosure of Clinical Data
• Labeling Changes
• Active Monitoring of Adverse Events
• Direct-to-Consumer Advertising
• Medicare Improvements for Patients and Providers Act of 2008

Select Proposed Legislation in the 110th Congress

• Pharmaceutical Market Access and Drug Safety Act: Addressing the Issue of Drug Importation
• Prior Activities on the Importation Front
• How Will S. 242 Fare?
• Healthcare Information Technology Acts
• The Wired for Health Quality Act
• The Healthcare Enterprise Integration Act
• The PRO(TECH)T Act
• Health IT: Potential Upsides for Biopharma
• Access, Compassion, Care and Ethics for Seriously Ill Patients (ACCESS) Act
• Stem Cell Research
• Biologics Price Competition and Innovation Act of 2007: Focus on Biosimilars

All Eyes on the White House

• Overview of the Race for the Presidency
• President McCain: Implications for Biopharma
• President Obama: Implications for Biopharma
• Timeline for Change

Outlook: Issues to Watch on the National Healthcare Front

• Rise in Personalized Medicine
• Scrutiny of Access to Medicine
• Shift in Patient Paradigm
• Expert Commentary
• Building an Operational REMS Framework to Enhance Product Value
• Jeffrey Stoddard, M.D., Vice President, Medical and Scientifi c Affairs, Risk Management and Postmarketing Programs, Covance, Periapproval Services Edgar H. Adams, Sc.D., Executive Director, Epidemiology, Covance, Periapproval Services

Tables

• 1. Select U.S. Health-Related Statistics
• 2. Factors Necessitating the FDA to Issue REMS
• 3. FDA-Approved Products That Must Have REMS in Place by September 21, 2008
• 4. Select Federal Health IT Initiatives
• 5. U.S. Patent Expiries of Key Biologics
• 6. Prices of Leading Biologics in the Major Markets as a Percentage of U.S. Prices
• 7. EMEA' s Adopted Biosimilar Guidelines as of August 2008
• 8. Comparison of Presidential Candidates' Positions on Biopharma Issues

Figures

• 1. U.S. Healthcare Statistics Relative to Select Other Nations
• 2. U.S. Health Expenditures by Expense Type
• 3. Sales of Prescription Drugs, 2003-2007
• 4. Number of Prescriptions Dispensed in the United States, 2003-2007
• 5. Number of DDMAC Warning Letters, 1998-2008
• 6. Drug Reimportation Timeline: Politics, Patients' Rights, and Pharmaceutical Industry Lobbying
• 7. Mean Length of FDA Approval Processes for New Molecular Entities
• 8. Main Constraints on Biogeneric Use: U.S. Physicians
• A. Risk Management Framework

相關商品

規章相關市場調查報告書

歐洲的醫藥品支付制度和各適應症的藥價設定
Reimbursement in Europe and Indication-Specific Pricing
價格 : US $ 3835
出版日期 : 2011年12月

日本的藥價，回本，法規的最新資訊
Japan: Pricing, Reimbursement and Regulatory Update
價格 : US $ 1900
出版日期 : 2011年11月

拉丁美洲醫藥品產業展望
The Outlook for Pharmaceuticals in Latin America
價格 : US $ 3630
出版日期 : 2011年11月

Decision Resources, Inc.發行的製藥相關市場調查報告書

傳染病疫苗開發平台:競爭檢討

Special Report: The Infectious Disease Vaccine Pipeline--A Competitive Review

價格 : US $ 9200

出版日期 : 2011年06月

感染疾病疫苗:未滿足需求和對醫藥品產業來說的機會

Special Report: Infectious Disease Vaccines--Unmet Needs and Opportunities for Pharma

價格 : US $ 9200

出版日期 : 2011年06月

自閉症譜系障礙:高未滿足需求創造出很大的市場機會

Special Report: Autism Spectrum Disorders--High Unmet Needs Create Significant Market Opportunities

價格 : US $ 9200

出版日期 : 2011年06月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!